Search results for "Color"

showing 10 items of 2721 documents

BMP7v induces cancer stem cells differentiation and enhances chemotherapy response in colorectal cancer

2014

Cancer stem cells (CSCs), characterized by high levels of ATP-binding cassette, anti-apoptotic molecules, active DNA-repair and slow replication capacities, surviving to conventional anti-cancer therapies, able to eradicate only the highly proliferating tumor cells, represent the elective target for new therapies. Colorectal CSCs (CR-CSCs) represent a powerful tool for preclinical validation of target therapies. In particular the elucidation of the mechanisms that govern stem cell survival and differentiation appears very essential for the identification of new molecular targets in cancer therapy. Among the molecules that govern these processes there are the Bone Morphogenetic Proteins (BMP…

Settore MED/04 - Patologia GeneraleCancer stem cellBone Morphogenetic Proteins (BMPs)Colorectal cancer
researchProduct

Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?

2022

Alterations in short-repetitive DNA sequences, known as microsatellite instability (MSI), can reflect deficiencies in Mismatch Repair (MMR) system which represents a major player in DNA integrity maintenance. The incidence of MSI-H/dMMR has been shown to be variable depending on the tumor type. Several studies confirmed that dMMR/MSI status, although less frequent than PD-L1 expression, may better predict response to immune-checkpoint inhibitors (ICIs) in patients with solid tumors. In October 2016, the FDA granted pembrolizumab as breakthrough therapy for the treatment of non-CRC, MSI-H/dMMR tumors, providing, for the first time, a tumor-agnostic indication. In the next future, the tissue-…

Settore MED/06 - Oncologia MedicaHematologyMMR deficiencyColorectal cancerMMRPD-1/PD-L1DNA Mismatch RepairTumor-agnostic therapyOncologyNeoplasmsSolid tumorsHumansMicrosatellite InstabilityImmunotherapyColorectal NeoplasmsMSI
researchProduct

The prognostic role of KRAS and BRAF in patients undergoing surgical resection of colorectal cancer liver metastasis: a systematic review and meta-an…

2016

Background: Clinical trials investigated the potential role of both KRAS and BRAF mutations, as prognostic biomarkers, in colorectal cancer (CRC) patients who underwent surgical treatment of liver metastasis (CLM), showing conflicting results. This meta-analysis aims to review all the studies reporting survival outcomes (recurrence free survival (RFS), and/or overall survival (OS)) of patients undergoing resection of CLM, stratified according to KRAS and/or BRAF mutation status. Materials and Methods: Data from all published studies reporting survival outcomes (RFS and/or OS) of CRC patients who received resection of CLM, stratified by KRAS and/or BRAF mutation status were collected by sear…

Settore MED/06 - Oncologia MedicaKRAS BRAF prognostic colorectal cancer liver metastasis meta-analysis
researchProduct

Colorectal cancer: An update on the effects of lycopene on tumor progression and cell proliferation

2017

Colorectal cancer (CRC) is one of the most common cancers worldwide. Various factors, including oxidative stress, where excessive productions of reactive oxygen species (ROS) and reactive nitrogen species (RNS) occur, contribute to its pathogenesis. Numerous studies have investigated the effect of antioxidant substances derived from food such as fruits and vegetables; however, data on Lycopene are still rare. Studies on HT-29 colorectal cancer cells and on animal models have shown that lycopene has effects on cell proliferation and on the progression of the CRC by interacting with various cellular signaling pathways. This analysis of the literature focused on the antioxidant effect of lycop…

Settore MED/06 - Oncologia MedicaSettore BIO/11 - Biologia MolecolareNeoplasms ExperimentalCarotenoidsSettore MED/18 - Chirurgia GeneraleLycopeneAnimalsHumanscolorectal cancer antioxidant effects cell proliferationColorectal NeoplasmsReactive Oxygen SpeciesCell ProliferationSignal Transduction
researchProduct

RUOLO DELL’ECOCOLOR DOPPLER TISSUTALE NELLA VALUTAZIONE DELLA CARDIOTOSSICITÀ DA CHEMIOTERAPICI

2010

Settore MED/06 - Oncologia MedicaSettore BIO/14 - FarmacologiaECOCOLOR DOPPLER TISSUTALE CARDIOTOSSICITÀ CHEMIOTERAPICISettore MED/11 - Malattie Dell'Apparato Cardiovascolare
researchProduct

“Bevacizumab (Bev) with irinotecan (IRI), folinic acid (FA), and 5-fluorouracil (FU) i.v. every 2 weeks (BIFF regimen) as first-line treatment for me…

2009

Settore MED/06 - Oncologia Medicabevacizumab metastatic colorectal cancer
researchProduct

“Bevacizumab (BEV),irinotecan (IRI), folinic acid (FA) and fluorouracil (FU) every 2 weeks (BIFF regimen) as first-line treatment for metastatic colo…

2009

Settore MED/06 - Oncologia Medicabevacizumabchemotherapymetastatic colorectal cancer
researchProduct

MicroRNAs in Colorectal Cancer Drug Resistance: Shooters become Targets

2013

Copyright: © 2013 Fanale D, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. MicroRNAs (MiRNAs) are involved in the regulation of several biological processes such as development, differentiation, metabolism, apoptosis and proliferation. Recently, it has been shown that deregulated expression of miRNAs are present in different human cancers, suggesting a potential role in carcinogenesis [1,2]. Recent evidence suggests that miRNAs may represent potential new therapeutic approaches in patients with dru…

Settore MED/06 - Oncologia Medicabusiness.industryColorectal cancerGene regulatory networkmicroRNA drug resistance colorectal cancerDrug resistanceComputational biologyCreative commonsBioinformaticsmedicine.disease_causemedicine.diseaselaw.inventionlawmicroRNAMedicineSuppressorbusinessCarcinogenesisGeneJournal of Carcinogenesis & Mutagenesis
researchProduct

“Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colo…

2009

PURPOSE: Oxaliplatin combined with either fluorouracil/leucovorin (OXAFAFU) or capecitabine (OXXEL) has a demonstrated activity in metastatic colorectal cancer patients. We aimed at comparing these two regimens in terms of response rate (RR), safety, progression-free survival (PFS), and quality of life (QoL) of patients. METHODS: A total of 322 patients with metastatic colorectal cancer were randomized to receive biweekly: oxaliplatin 100 mg/m(2) i.v. on day 1, capecitabine 1,000 mg/m(2) orally twice daily from day 1 to day 11 (OXXEL); or oxaliplatin 85 mg/m(2) i.v. on day 1; 6S-leucovorin 250 mg/m(2) i.v. and fluorouracil 850 mg/m(2) i.v. on day 2 (OXAFAFU). RESULTS: Eleven complete and 42…

Settore MED/06 - Oncologia MedicacapecitabineoxaliplatinOXXEL regimenOXAFAFU regimencolorectal carcinomarandomized trial
researchProduct

Differing expression of metalloprotease and of adhesion molecules in signet-ring cell and intestinal colorectal carcinoma.

2009

Abstract. Background: Pure signet-ring cell colorectal carcinoma (SRCC) is an infrequent and highly malignant histological variant of colorectal cancer (CRC), while it is present as a histological component in colorectal carcinomas more frequently. Materials and Methods: The aim of this work was to widen the knowledge of the biological factors involved in the pathogenesis and aggressiveness of SRCC by the identification and evaluation of possible molecular abnormalities. By means of immunohistochemistry the expression of the proteolytic degradation enzyme matrix metalloprotease (MMP)-1, that is a collagenase specifically degrading collagens I, II, III and of the adhesion proteins Ecadherin,…

Settore MED/08 - Anatomia PatologicaColorectal cancer cadherin catenin fibronectin metalloprotease-1 signet-ring cell.
researchProduct